

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

January 27, 2015

(Date of Report - date of earliest event reported)

Tekmira Pharmaceuticals Corporation
(Exact Name of Registrant as Specified in Its Charter)

British Columbia, Canada
(State or Other Jurisdiction of
Incorporation or Organization)

001-34949
(Commission File Number)

98-0597776
(I.R.S. Employer
Identification No.)

100-8900 Glenlyon Parkway
Burnaby, British Columbia, Canada
(Address of Principal Executive Offices)

V5J 5J8
(Zip Code)

(604) 419-3200
(Registrant's Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On January 27, 2015, management of Tekmira Pharmaceuticals Corporation, a British Columbia corporation (“Tekmira”), gave an investor presentation regarding Tekmira’s proposed merger pursuant to that certain Agreement and Plan of Merger and Reorganization, dated January 11, 2015, by and among Tekmira, TKM Acquisition Corporation, a Delaware corporation and a wholly-owned subsidiary of Tekmira, and OnCore Biopharma, Inc. A copy of the Presentation Slide Deck used by Tekmira during the investor presentation is attached hereto as Exhibit 99.1 and incorporated herein by reference in its entirety.

IMPORTANT ADDITIONAL INFORMATION FILED WITH THE SEC

Tekmira has filed with the Securities and Exchange Commission (the “SEC”) a preliminary proxy statement in connection with the proposed Merger and plans to mail to its stockholders a definitive proxy statement in connection with the proposed Merger. The definitive proxy statement will contain important information about the proposed Merger and related matters. **INVESTORS AND STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT CAREFULLY IN ITS ENTIRETY WHEN IT BECOMES AVAILABLE.** Investors and stockholders will be able to obtain free copies of the proxy statement and other documents filed with the SEC by Tekmira through the SEC’s website at www.sec.gov and from Tekmira by contacting Investor Relations by telephone at (604) 419-3200 or upon written request addressed to our corporate secretary at Tekmira Pharmaceuticals Corporation, 100 – 8900 Glenlyon Parkway, Burnaby, BC, Canada, V5J 5J8 or by going to Tekmira’s Investor section on its corporate web site at www.tekmira.com.

Tekmira and its executive officers and directors may be deemed to be participants in the solicitation of proxies from the stockholders of Tekmira in connection with the proposed Merger. Information regarding the interests of these executive officers and directors in the transaction described herein will be included in the proxy statement described above. Additional information regarding these executive officers and directors is also included in Tekmira’s Annual Report on Form 10-K, which was filed with the SEC on March 28, 2014, and is supplemented by other public filings made, and to be made, with the SEC by Tekmira. The Annual Report on Form 10-K and other public filings are available free of charge through the SEC’s website at www.sec.gov and from Tekmira by contacting Investor Relations by telephone at (604) 419-3200 or upon written request addressed to our corporate secretary at Tekmira Pharmaceuticals Corporation, Tekmira Pharmaceuticals Corporation, 100 – 8900 Glenlyon Parkway, Burnaby, BC, Canada, V5J 5J8 or by going to Tekmira’s Investor section on its corporate web site at www.tekmira.com.

Safe Harbor for Forward Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements in this Current Report on Form 8-K include statements about the proposed merger of Tekmira and OnCore; the anticipated closing of the merger; calling, holding and obtaining Tekmira shareholder approval for the merger; the executives and board members of the combined company.

With respect to the forward-looking statements contained in this Current Report on Form 8-K, Tekmira has made numerous assumptions regarding, among other things: the ability to obtain required shareholder and regulatory approval for the merger and the timing thereof; the ability to satisfy all conditions for the closing of the merger; and the subsequent integration of Tekmira and OnCore business and operations. While Tekmira considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.

Additionally, there are known and unknown risk factors which could cause Tekmira's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained herein. Known risk factors include, among others: the ability of the parties to consummate the proposed merger; satisfaction of closing conditions to the consummation of the proposed merger; the ability to obtain Tekmira shareholder approval for the merger; the ability to obtain any required regulatory approvals and the timing of such, and conditions that may be imposed on the merger therefrom; the impact of the announcement or the closing of the merger on Tekmira's relationships with its employees, existing customers or potential future customers; the ability of Tekmira to successfully integrate OnCore's operations and employees in a timely and efficient manner; the risks detailed in Tekmira's Current Reports on Form 8-K and Form 8-K/A filed with the SEC on January 12, 2015 and January 26, 2015, respectively; and such other risks detailed in Tekmira's Quarterly Report on Form 10-Q filed with the SEC on November 7, 2014, and other continuous disclosure filings which contain and identify important factors that could cause actual results to differ materially from those contained in the forward-looking statements. Forward-looking statements contained in this Current Report on Form 8-K speak only as of the date hereof. Tekmira assumes no obligation to update any forward-looking statement contained in this Current Report on Form 8-K, except as required by law.

Item 9.01. Financial Statements and Exhibits.

(a) Financial Statements of business acquired.

Not applicable

(b) Pro forma financial information.

Not applicable

(c) Shell company transactions.

Not applicable

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	Presentation Slide Deck, dated January 27, 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 27, 2015

**TEKMIRA PHARMACEUTICALS
CORPORATION**

By: /s/ Bruce G. Cousins
Name: Bruce G. Cousins
Title: Executive Vice President & Chief
Financial Officer

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
99.1	Presentation Slide Deck, dated January 27, 2015

Creating a Leading Global HBV Therapeutics Company

Transaction Overview | January 27, 2015



Forward Looking Statements

This presentation contains "forward-looking statements" or "forward-looking information" within the meaning of applicable securities laws (collectively, "forward-looking statements"). Forward-looking statements in this presentation include statements about, among others: the proposed merger of Tekmira and OnCore; developing a curative regime for HBV; providing a finite treatment regimen; the global market opportunity in HBV and creation of significant long-term value for shareholders; expectations of creating a leading portfolio of therapeutic approaches to cure HBV; addressing a significant unmet medical need; the timing of the closing of the merger with OnCore; Tekmira shareholder approval and regulatory approval for the merger; the market for Hepatitis B in relation to Hepatitis C; rapid development timelines and maximization of value; potential novel drug candidates and technologies; advancing non-HBV programs; and the quantum of the implied market value of the combined company.

With respect to the forward-looking statements contained in this presentation, Tekmira has made numerous assumptions regarding, among other things: the ability to satisfy all conditions for the closing of the merger, including receipt of required shareholder and regulatory approvals; the elements factored into the calculation of the implied market value of the combined company are correct and will remain unchanged as at closing of the merger; and the effectiveness and commercial viability of the combined company's products. While Tekmira considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.

Forward-looking statements herein involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the ability of the parties to consummate the proposed merger; satisfaction of closing conditions (including shareholder and regulatory approval) to the consummation of the proposed merger; the ability of Tekmira to successfully integrate OnCore's operations and employees in a timely and efficient manner; the ability to realize anticipated synergies and costs savings of the proposed merger; the combined company's product pipeline may not prove to be effective or commercially beneficial; there can be no assurance that the implied market value of the combined company as disclosed herein is accurate or reflects the actual value of the combined company; non-HBV assets may not prove to have any commercial significance to the combined company; the combined company may not be able to raise additional financing required to fund further research and development, clinical studies, and obtain regulatory approvals, on commercially acceptable terms or at all; and economic and capital market conditions.

A more complete discussion of the risks and uncertainties facing Tekmira should be reviewed and appear in Tekmira's news release dated January 11, 2015 and Tekmira's continuous disclosure filings which are available at www.sec.gov or www.sedar.com. Tekmira disclaims any obligation to update any forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.

IMPORTANT ADDITIONAL INFORMATION WILL BE FILED WITH THE SEC

Tekmira plans to file with the Securities and Exchange Commission (the "SEC") and mail to its stockholders a proxy statement in connection with the proposed Merger. The proxy statement will contain important information about the proposed Merger and related matters. INVESTORS AND STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT CAREFULLY IN ITS ENTIRETY WHEN IT BECOMES AVAILABLE. Investors and stockholders will be able to obtain free copies of the proxy statement and other documents filed with the SEC by Tekmira through the SEC's website at www.sec.gov and from Tekmira by contacting Investor Relations by telephone at (604) 419-3200 or upon written request addressed to our corporate secretary at Tekmira Pharmaceuticals Corporation, 100 – 8900 Glenlyon Parkway, Burnaby, BC, Canada, V5J 5J8 or by going to Tekmira's Investor section on its corporate web site at www.tekmira.com.

Tekmira and its executive officers and directors may be deemed to be participants in the solicitation of proxies from the stockholders of Tekmira in connection with the proposed Merger. Information regarding the interests of these executive officers and directors in the transaction described herein will be included in the proxy statement described above. Additional information regarding these executive officers and directors is also included in Tekmira's Annual Report on Form 10-K, which was filed with the SEC on March 28, 2014, and is supplemented by other public filings made, and to be made, with the SEC by Tekmira. The Annual Report on Form 10-K and other public filings are available free of charge through the SEC's website at www.sec.gov and from Tekmira by contacting Investor Relations by telephone at (604) 419-3200 or upon written request addressed to our corporate secretary at Tekmira Pharmaceuticals Corporation, Tekmira Pharmaceuticals Corporation, 100 – 8900 Glenlyon Parkway, Burnaby, BC, Canada, V5J 5J8 or by going to Tekmira's Investor section on its corporate web site at www.tekmira.com.

Chronic HBV – *greatest global unmet medical need*

350M people chronically infected with HBV



● Chronic HBV Infections ● HBV Genotypes (A-H)

780K people die every year
due to the consequences of HBV


Our Goal – *an all oral, curative therapy for HBV*

- HBV biology is complex
 - *More complex than HCV*
- HBV persists by
 1. Replicating continually in liver hepatocytes
 2. Expressing viral antigens that suppress the immune response
 3. Establishing a stable cccDNA reservoir in the nucleus
- Curative therapy will require a combination of drugs that overcome these *‘three pillars’* of viral persistence
- We have assembled a unique set of clinical & preclinical assets which target these *‘three pillars’* of viral persistence
 - 8 assets under one roof
 - Enables efficient development of drug combinations

Our Strategy

- Provide a cure by delivering multiple mechanisms of action against the virus
 - Aggressively suppress viral replication
 - Stimulate or reactivate the immune system
 - Eliminate cccDNA
- Provide a finite treatment regimen

To succeed in achieving HBV Cure,
all facets of HBV persistence need
to be addressed



Transaction Highlights

- Combined company well positioned to capitalize on the global market opportunity in HBV and create significant long-term value for shareholders
- Creates the industry's leading portfolio of therapeutic approaches to cure HBV, addressing a significant unmet medical need
- Eight unique drug candidates to be used in combination regimes
- Brings together proven management teams and scientific leadership, including former Pharmasset executives
- Transaction has the unanimous support of the Tekmira and OnCore Boards of Directors
- Close expected in 60-90 days, subject to the approval of Tekmira shareholders

Proven Leadership

- Mark Murray, Chief Executive Officer (Tekmira)
- Patrick Higgins, President and Chief Operating Officer (OnCore, former Pharmasset)
- Bruce Cousins, Chief Financial Officer (Tekmira)
- Michael Sofia, Chief Scientific Officer (OnCore, former Pharmasset)
- William Symonds, Chief Development Officer (OnCore, former Pharmasset)
- Mark Kowalski, Chief Medical Officer (Tekmira)
- Bryce Roberts, Chief Legal Officer (OnCore, former Pharmasset)
- Michael McElhaugh, Chief Business Officer (OnCore, former Pharmasset)
- Mike Abrams, Chief Discovery Officer (Tekmira)

Building the “HBV Solutions” Company

- Hepatitis B is a bigger market than Hepatitis C
- Building a portfolio of HBV assets that will lead to curative therapy
- Differentiating from the potential competition in multiple ways:
 1. Utilization of combination therapy with a three-pillar approach
 2. Nine compounds or compound series against eight distinct mechanisms of action on viral target
 3. Ultimately, driving to oral mechanisms of action: equally as important as in hepatitis C
- HBV cure will evolve from parental to oral cure similar to HCV, but on faster development path
- Of all mechanisms of action, we believe the BACKBONE to curing HBV is eradicating cccDNA
 - ✓ Two direct approaches and two indirect approaches
 - ✓ Turns HBV into an HCV-like disease
- Because of the need for combination therapy, we believe each drug is worth more in the hands of a single company that also owns the other mechanisms of action
 - ✓ Increases chances for success
 - ✓ Spreads risks across multiple assets
- Not married to one product, married to the strategy
 - ✓ Changes the drug development paradigm
 - ✓ More efficient use of capital
- Combination of leading RNAi technology experts with former executives from Pharmasset, who successfully developed the sofosbuvir-based HCV cure regimen

OnCore-Tekmira Development Pipeline

Candidate/ Program	Addressed HBV Persistence Factor			Stage of Development				Source of Candidate / Program
	HBV Replication Inhibition	Immune System Stimulation/ Reactivation	cccDNA Formation Inhibition/ Elimination	Preclinical				
				Research	Lead Optimization	IND Enabling	Phase 1	
TKM-HBV								Tekmira
OCB-030 (Cyclophilin Inhibitor)								Licensed from NeuroVive
CYT003 (TLR9 Agonist)								Licensed from Cytos
Capsid Assembly Inhibitors (2 Candidates)								Acquisition of Enantigen and license from Blumberg Institute/Drexel University
Surface Antigen Secretion Inhibitor								Acquisition of Enantigen
cccDNA Formation Inhibitor								License from Blumberg/Drexel
STING Agonist								License from Blumberg/Drexel
cccDNA Epigenetic Modifier								License from Blumberg/Drexel


Relationship with Baruch S. Blumberg Institute

Blumberg Institute Is One of the Leading Research Institutes Focused on HBV

- License Agreements with Blumberg and Drexel University (Drexel) — February 2014 and November 2014
 - cccDNA Inhibitors
 - Capsid Assembly Inhibitors
 - Epigenetic Modifiers of cccDNA
 - STING Agonists
- Patent License Agreements with Blumberg and Drexel via Enantigen Acquisition — October 2014
 - Surface Antigen Secretion Inhibitors
 - Capsid Assembly Inhibitors
- Research Funding and Collaboration Agreement with Blumberg — October 2014
 - ✓ Research collaboration and funding agreement - exclusive rights to in-license any IP generated through relationship
 - ✓ Three-year term, renewable option for an additional three years
 - ✓ Includes identification of novel targets, new therapeutic compound series, and proprietary assays
 - ✓ Supplements our internal discovery efforts with 30 to 40 dedicated HBV scientists


**Integral part of HBV portfolio with research collaboration
a continued source of potential novel drug candidates and technologies**

TKM-HBV: Targeting Multiple HBV Transcripts



- Design an anti-HBV RNAi Trigger 'payload' that is:
 - **Potent** - reduces viral protein production, especially HBsAg
 - **Universal** - effective against all genotypes
- All three triggers target the 2.1/2.4 kb sAg encoding mRNAs and also cleave 3.5 kb and 0.7 kb mRNA and pgRNA with potential for additional therapeutic benefit by reducing eAg, HBx, and core Ag

Combination Development Strategy



*Will initially combine with existing NUC therapy

Advancing Non-HBV Programs

Focus	Indication	Product	Pre-				
			Research	Clinical	Phase I	Phase II	Phase III
Cancer	Gastrointestinal Neuroendocrine Tumors	TKM-PLK1: GI-NET					
	Adrenocortical Carcinoma	TKM-PLK1: ACC					
	Hepatocellular Carcinoma	TKM-PLK1: HCC					
Anti-Viral	Ebola Virus Infection	TKM-Ebola					
	Ebola Virus Infection	TKM-Ebola-Guinea					
	Marburg Virus Infection	TKM-Marburg					
Metabolic	Rare Forms of Hypertriglyceridemia	TKM-HTG					
	Glycogen Storage Disorder Type IV	TKM-GSD					
	Alcohol Use Disorder	TKM-ALDH					

OnCore-Tekmira Transaction Details

- OnCore will become a wholly-owned subsidiary of Tekmira
- Merger of equals as determined by the treasury stock method
- Implied market value of the combined company, based on the closing price of Tekmira common shares on the NASDAQ Global Market on January 9, 2015, is approximately USD\$750 million
- Merger is subject to approval of a majority of TKMR shareholders
- The transaction is expected to close in the first half of 2015

Conclusion

- Combined company well positioned to capitalize on the global market opportunity in HBV and create significant long-term value for shareholders
- Creates the industry's leading portfolio of therapeutic approaches to cure HBV, addressing a significant unmet medical need
- 8 unique drug candidates to be used in combination regimes
- Brings together proven management teams and scientific leadership, including former Pharmasset executives
- Tekmira Board of Directors unanimously recommends that Tekmira shareholders vote FOR the proposed transaction

Creating a Leading Global HBV Therapeutics Company

Transaction Overview | January 27, 2015

Tekmira

ONCORE
BIOPHARMA, INC.